ATHA Athira Pharma Inc: רווח למניה לשנה מתגלגלת

Athira Pharma, Inc. (ATHA) is developing unique neuron regeneration methods, providing the company with significant pricing power. The annual net income per share growth rate (TTM) shows a pivot driven by the scaling of phosphgonimetone trials and planned R&D cash burn. The current value of 65.70 serves as a baseline indicator of the company's fundamental stability during its fight against Alzheimer's disease.
Athira Pharma, Inc. - פילוחים אנליטיים ומדדי מפתח (ATHA)

Athira Pharma, Inc. (ATHA) focuses on the regeneration of neural connections in Alzheimer's disease, which dictates high capital intensity and makes profits dependent on clinical trial stages. This indicator measures the annual growth rate of net income per share over a rolling year, separating operational growth from one-time accounting adjustments. By analyzing the historical EPS YoY TTM dynamics on GURU.Markets, an investor can distinguish sustainable business development from speculative impulses.